• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Biomerica Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    12/16/25 8:19:33 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BMRA alert in real time by email
    false 0000073290 0000073290 2025-12-12 2025-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 12, 2025

     

    BIOMERICA, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-37863   95-2645573

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    17571 Von Karman Avenue, Irvine, California   92614
    (Address of Principal Executive Offices)   (Zip Code)

     

    (949) 645-2111

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.08 per share   BMRA   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    Biomerica, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) on December 12, 2025. As of October 15, 2025, the record date for the 2025 Annual Meeting, the Company had 2,947,966 shares of common stock outstanding and entitled to vote, of which 1,554,917 shares of common stock were present in person or represented by proxy and entitled to vote at the 2025 Annual Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2025 Annual Meeting.

     

    Proposal No. 1: The Company’s stockholders elected each of the five nominees named below to serve on the Company’s Board of Directors (the “Board”) until the next annual meeting of stockholders of the Company and until his or her successor has been elected and qualified or until his or her earlier resignation, death or removal.

     

    Nominee  Votes For  Votes Withheld  Broker Non-votes
    Zackary Irani  428,961  76,998  1,048,958
    Allen Barbieri  381,206  124,753  1,048,958
    Eric Bing Chin, CPA  388,403  117,556  1,048,958
    Gary Huff  422,680  83,279  1,048,958
    David Moatazedi  361,240  144,719  1,048,958

     

    Proposal No. 2: The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to our named executive officers.

     

    Votes For  Votes Against  Votes Abstaining  Broker Non-Votes
    411,157  87,344  7,458  1,048,958

     

    Proposal No. 3: The Company’s stockholders ratified the selection of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ending May 31, 2026.

     

    Votes For  Votes Against  Votes Abstaining  Broker Non-Votes
    1,472,716  73,443  8,758  —

     

    Proposal No. 4: The Company’s stockholders approved the amendment to the Company’s 2024 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance under the 2024 Stock Incentive Plan by 200,000 shares.

     

    Votes For  Votes Against  Votes Abstaining  Broker Non-Votes
    371,339  131,430  3,190  1,048,958

     

    Proposal No. 5: The Company’s stockholders approved the amendment to the Company’s Amended and Restated Certificate of Incorporation to authorize the Board, at their discretion, to effect an increase in the number of authorized shares of the Company’s common stock from 25,000,000 to 300,000,000.

     

    Votes For  Votes Against  Votes Abstaining  Broker Non-Votes
    1,028,102  513,650  13,165  —

     

    Proposal No. 6: The Company’s stockholders approved an adjournment of the Annual Meeting, if necessary or appropriate, including to establish a quorum.

     

    Votes For  Votes Against  Votes Abstaining  Broker Non-Votes
    1,349,014  187,592  18,311  —

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      BIOMERICA, INC.
         
    Date: December 16, 2025 By: /s/ Zackary S. Irani
        Zackary S. Irani
        Chief Executive Officer

     

     

     

    Get the next $BMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio

    Authorization Covers Multiple Screening Tests for Cancer and Chronic Disease Risk Detection • Portfolio includes tests for colorectal disease, breast self exam, prostate disease, kidney disease, and H. pylori infection • Designed for early detection of conditions that are related to the most common cancers and chronic diseases • Rapid, easy-to-use, and cost-effective screening for mass and individual use IRVINE, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced today that the Egyptian Drug Authority (EDA) has granted authorization for Biomerica's complete portfolio of rapid tests, enabling broad access

    12/11/25 8:08:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand

    Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service ExpansionComprehensive CDMO services now featured on Biomerica's updated website IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced medical diagnostic solutions, today announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to meet accelerating market demand. The Company is enhancing its capabilities to provide greater value and reliability of product development and manufacturing across the entire development lifecycle for diagnostic innovators worldwide. With more than 40 years of expertise in as

    11/6/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.

    - Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation's Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica's Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, to market Biomerica's inFoods® Irritable Bowel Syndrome (IBS) test in the United States, excluding New York State. Henry Schein's powerful nationwide distribution network, comprised of m

    10/16/25 8:19:00 AM ET
    $BMRA
    $HSIC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities

    $BMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chin Eric claimed ownership of 10,000 units of Restricted Stock (SEC Form 3)

    3 - BIOMERICA INC (0000073290) (Issuer)

    6/6/25 9:29:04 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Emerson Jane was granted 85,000 shares, increasing direct ownership by 120% to 156,000 units (SEC Form 4)

    4 - BIOMERICA INC (0000073290) (Issuer)

    12/17/24 7:30:09 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Coste Catherine was granted 85,000 shares, increasing direct ownership by 194% to 128,790 units (SEC Form 4)

    4 - BIOMERICA INC (0000073290) (Issuer)

    12/17/24 7:30:05 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    SEC Filings

    View All

    Biomerica Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - BIOMERICA INC (0000073290) (Filer)

    12/16/25 8:19:33 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form DEFA14A filed by Biomerica Inc.

    DEFA14A - BIOMERICA INC (0000073290) (Filer)

    10/23/25 4:15:04 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form DEF 14A filed by Biomerica Inc.

    DEF 14A - BIOMERICA INC (0000073290) (Filer)

    10/20/25 5:05:17 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors

    Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member. Mr. Huff brings decades of leadership experience in the diagnostics and healthcare services industry, including serving as Chief Executive Officer of LabCorp Diagnostics, one of the world's largest clinical laboratories. Mr. Huff is a hands-on, inspirational,

    10/8/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial Officer

    Brings 20+ years of revenue growth leadership in laboratory testing, clinical diagnostics and global expansionLed successful organizational turnarounds and growth strategies at both Boston Heart Diagnostics and Genova DiagnosticsExtensive track record in commercializing advanced laboratory testing, driving growth and payer strategies IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ:BMRA), a global biomedical company leading the way in innovative gastroenterology solutions, today announced the appointment of Scott Madel as Chief Commercial Officer. Scott brings more than two decades of cross-functional expertise in healthcare, diagnostics, commercialization, and pa

    6/26/25 8:19:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair

    Mr. Chin brings over 20 years of financial experience across public and private healthcare organizationsMr. Chin currently serves as CFO of Akido Labs where he successfully helped raise $60 million in a recent financingMr. Chin's appointment strengthens Biomerica's corporate governance and financial oversight as Biomerica scales commercialization efforts IRVINE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global biomedical company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products, today announced that Eric B. Chin has been appointed to the Company's Board of Directors, effective June 4, 2025. Mr. Chin will serve

    6/6/25 9:30:00 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    Financials

    Live finance-specific insights

    View All

    Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022

    InFoods® IBS Data Receives American College of Gastroenterology Presidential Award (ACG) Following Presentation at Annual Scientific Meeting  Trial Data Shows InFoods® IBS Treatment Diet Significantly Improved Several IBS Symptoms Including Abdominal Pain Intensity (API): In Some Cases Better Than Certain Currently Marketed Drugs  Launch of InFoods® IBS Lab Developed Test Expected in Fiscal 3Q  Amazon Now Fulfills Sales of Aware® Breast Self Exam and EZ Detect™ Colon Disease Tests IRVINE, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- IRVINE, CABiomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products, today reported its second quarter fiscal 2023 fina

    1/13/23 6:39:00 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biomerica Inc.

    SC 13G/A - BIOMERICA INC (0000073290) (Subject)

    11/14/24 4:19:51 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Biomerica Inc. (Amendment)

    SC 13G/A - BIOMERICA INC (0000073290) (Subject)

    2/14/24 9:00:06 AM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Biomerica Inc.

    SC 13G - BIOMERICA INC (0000073290) (Subject)

    2/9/24 3:06:57 PM ET
    $BMRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care